• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Novartis > February 03, 2011

      Novartis To Acquire Genoptix

      Posted Atpharmtech.findpharma.com

      Novartis is looking to advance its personalized medicine treatment programs by entering into a definitive agreement to acquire Genoptix, a laboratory offering personalized diagnostic services, for approximately $470 million or $25 per share. According to Novartis, the acquisition will support the development of companion diagnostic programs, particularly in oncology, and advance the company’s ability to define and monitor personalized treatment programs.

      Genoptix, based in California (USA), employs approximately 500 people and will become part of Novartis Molecular Diagnostics, a unit within the Novartis Pharmaceuticals Division. According to a press statement, the Novartis tender offer represents a premium of approximately 27% over Genoptix’s January 21 share price.

      "The acquisition of the Genoptix medical laboratory will serve as a strong foundation for our individualized treatment programs," Joseph Jimenez, CEO of Novartis, said in the statement. “By integrating Genoptix within Novartis, we can greatly enhance the value we add to patients, clinicians, payers and society."

      The Genoptix Board of Directors has unanimously approved the transaction and recommended that stockholders tender their shares and adopt the merger agreement. In a Genoptix statement, CEO Tina S. Nova said: "We believe this transaction provides substantial value and liquidity to our stockholders. We are excited about becoming part of the Novartis Molecular Diagnostics unit and continuing to enhance the value that we bring to our core community oncologist customers.”

      The transaction is conditional upon the tender of at least a majority of the shares of Genoptix in the tender offer, receipt of regulatory approvals and other customary closing conditions. The transaction is expected to close within the first half of 2011.

      Feb 03, 2011


       

      Share this Article!

    Back to top^